This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Age 18-75 years old, male or female;
Diagnosis confirmed HCC by pathologically or clinically;
At least one measurable lesion;
Child-Pugh liver function grade A;
Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
Participants with any active, known or suspected autoimmune disorder;
Participants with hypertension which cannot be well controlled by antihypertensives;
Uncontrolled cardiac diseases or symptoms;